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Introduction
Over the past few decades, the incidence of esophageal cancer
(EC) has increased [1]. The most common histological type of
EC is esophageal squamous cell carcinoma (ESCC) [2]. The over-
all survival of patients with EC has improved due to better treat-
ment options such as neoadjuvant chemoradiotherapy, and the
treatment shift from esophagectomy to endoscopic resection
(ER) for early EC [3–5].
Compared to surgery, ER has lower morbidity and mortality
for early EC while maintaining equal curative outcomes [5].
Endoscopic mucosal resection (EMR) and endoscopic submuco-
sal dissection (ESD) are established treatment options when EC
is limited to the superficial layers [6]. ESD is recommended over
EMR for a selected number of adenocarcinomas larger than 15
mm with suspected submucosal invasion, and for all superficial
ESCCs except if submucosal invasion is suspected [7]. More-
over, ESD provides en bloc resection and it reduces the number
of recurrences compared to EMR [8, 9].
A major disadvantage of ER of large esophageal tumors,
however, is the high stricture rate after resection [10, 11]. Stric-
ture formation after ER of early EC with a mucosal defect≥75%
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ABSTRACT
Background and study aims A disadvantage of endo-
scopic resection (ER) of early esophageal cancer (EC) is the
high stricture rate after resection. A risk factor for stricture
development is a mucosal defect after ER of ≥75% of the
esophageal circumference. Stricture rates up to 94% have
been reported in these patients. The aim of this study was
to investigate the effectiveness of oral treatment with topi-
cal budesonide for stricture prevention after ER of early EC.
Patients and methods We performed a retrospective a-
nalysis of a prospective cohort study of patients who receiv-
ed topical budesonide after ER of EC between March 2015
and April 2020. The primary endpoint was the esophageal
stricture rate after ER. Stricture rates of our cohort were
compared with stricture rates of control groups in the lit-
erature.
Results In total, 42 patients were treated with ER and topi-
cal budesonide. A total of 18 of 42 patients (44.9%) devel-
oped a stricture. The pooled stricture rate of control groups
in the literature was 75.3% (95% CI 68.8%-81.9%). Control
groups consisted of patients with esophageal squamous
cell carcinoma with a mucosal defect after ER of≥75% of
the esophageal circumference. Comparable patients of our
cohort had a lower stricture rate (47.8% vs. 75.3%, P=
0.007).
Conclusions Topical budesonide therapy after ER for EC
seems to be a safe and effective method in preventing stric-
tures. The stricture rate after budesonide treatment is low-
er compared to the stricture rate of patients who did not re-
ceive a preventive treatment after ER reported in the litera-
ture.
Original article
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of the esophageal circumference is reported up to 94.1% in the
literature [10]. Esophageal strictures develop as a result of in-
flammation in the wound healing process of the mucosal defect
following ER [12]. Previous studies have shown that a mucosal
defect of ≥75% of the esophageal circumference was associat-
ed with esophageal stricture rates of 70% to 94% and it is re-
ported as a significant risk factor for stricture development
[10, 13–15]. Patients with strictures might suffer from dyspha-
gia with the need for endoscopic dilations, and patient quality
of life might substantially decrease [16]. In addition, endo-
scopic dilations are associated with an increased perforation
risk [17].
In an effort to reduce the stricture rate after ER of esopha-
geal tumors, preventive strategies have been investigated
[18]. For example, treatment with triamcinolone injections,
the use of polyglycolic acid sheet (PGA) with fibrin glue, preven-
tive endoscopic balloon dilation (EBD), and treatment with oral
prednisolone [16, 19–24]. Although these studies have shown
promising results in preventing strictures after ESD, limited pa-
tients were included and the optimal dose and duration of ster-
oids has not yet defined [16, 19–24]. The use of triamcinolone
injections in the esophagus has raised several concerns about
the safety and effectiveness [18]. Moreover, systemic therapy
with oral steroids is well known to have several side effects [25].
The question arises whether the use of topical steroids is ef-
fective in stricture prevention after ER of esophageal tumors,
due to its effect in the suppression of the inflammatory process
after ER [12]. Topical steroids have shown to be beneficial for
eosinophilic esophagitis treatment and have resulted in stric-
ture reduction after EMR of short Barrett’s segment [12, 26].
The aim of this study was to investigate the effectiveness of
oral treatment with topical budesonide for the prevention of
strictures after ER of EC (ESCC or esophageal adenocarcinoma
[EAC]). We hypothesized a lower esophageal stricture rate
when using topical budesonide compared to the stricture rate
in patients who did not receive a preventive treatment after
ER, reported in the literature. The secondary aim of this study
was to investigate whether the use of topical budesonide after
ER affects esophageal stricture treatment. We hypothesized
that less dilations were required in patients treated with topical
budesonide who developed a stricture after ER compared to pa-
tients who did not receive preventive treatment after ER, re-
ported in the literature.
Patient and methods
Study design
We performed a single-center, retrospective analysis of data
that has been prospectively collected in our ongoing registry
of ER of the esophagus at the Department of Gastroenterology
and Hepatology at the Erasmus MC, University Medical Center.
Patients treated with ER (EMR or ESD) for superficial ESCC or
EAC between March 2015 and April 2020 were retrospectively
included in this study. All patients that were deemed to have a
high chance of stricture development (i. e. patients with a mu-
cosal defect size after ER >50% of the esophageal circumfer-
ence) were treated with topical budesonide after ER in order
to prevent stricture development [15]. This was decided direct-
ly after ER by the treating endoscopist [A.K]. Patients were ex-
cluded if they had known intolerance to budesonide, candida
esophagitis, or immunocompromised conditions. Additionally,
patients were excluded from final analysis if they were treated
with prior ESD, EMR, radiotherapy, radiofrequency ablation, or
endoscopic dilation in the area where the current ER was per-
formed. These prior treatments could be of influence on stric-
ture development. This study was approved by the Medical
Ethical Review Committee of the Erasmus University MC in Rot-
terdam, the Netherlands [MEC-2019-0819].
Data collection
Data on patient and tumor characteristics were collected from
medical charts and endoscopy and pathology reports. An over-
view of collected characteristics can be found in Supplemen-
tary File 1. If a patient developed a second (metachronous) tu-
mor, the first tumor was included for final analysis to avoid bias.
ER was performed with either EMR or ESD, which was up to
the discretion of the endoscopist or dictated by the tumor
type. ESCC was always removed by ESD. EAC was only removed
by ESD when submucosal invasion was expected. EMR was per-
formed using the multiband mucosectomy method [27]. ESD
was carried out with a HybridKnife (ERBE Elektromedizin
GmbH, Tuebingen, Germany), lifting fluid contained saline
with indigo carmine and epinephrine [28]. All EMRs and ESDs
were performed by a single endoscopist [A.K.].
Treatment with budesonide after endoscopic
resection
The standard dose for topical budesonide was 2.3mg once a
day, 2.3mg twice a day or 1mg twice a day, for a duration of 6
weeks from the first day after ER. In general, if adjuvant therapy
(e. g. surgery or chemo-radiotherapy) was needed, budesonide
was still given for 6 weeks because strictures can develop short-
ly after ER. For every patient, this was discussed in a multidisci-
plinary team. Only if adjuvant therapy started within this 6-
week period, budesonide treatment discontinued earlier. The
budesonide dose depended on the availability of topical bude-
sonide in the pharmacy. In 2015, 2.3mg budesonide once a day
was given, and 2.3mg budesonide twice a day was given begin-
ning in 2016. In the last 6 months of inclusion, orodispersible
topical budesonide tablets of 1mg became available for eosino-
philic esophagitis (EoE) treatment wherefore this dose was cho-
sen. Because no orodispersible budesonide tablets were avail-
able for most of the study, the dispersible tablet from a budeso-
nide enema was used for oral intake. Patients were instructed
to let the tablet dissolve on the tongue and swallow the dis-
persed budesonide. This is a common off-label use of budeso-
nide in the treatment of EoE. Recently, a budesonide orodisper-
sible tablet has become available for treatment of EoE [29, 30].
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Endoscopic dilation
Endoscopic dilation was only performed when the patient had
dysphagia in combination with esophageal stenosis. Prophylac-
tic dilation was not performed. The type and interval of endo-
scopic dilation was up to the discretion of the endoscopist. In
general, two dilation techniques were used: bougie and balloon
dilation [31]. Dilations were usually done with a weekly repeti-
tion if necessary.
Study endpoints
The primary endpoint was the esophageal stricture rate in pa-
tients who received topical budesonide therapy after ER of early
EC. A stricture was defined as the inability to swallow solid food
and/or the inability to pass a standard diagnostic endoscope
(diameter: 9.9mm, GIF-H190 and GIF-H180 J, Olympus) which
resulted in the need for dilation. We only included strictures
that developed before adjuvant treatment (e. g. radiotherapy,
radiofrequency ablation, EMR, chemotherapy) started. Stric-
ture development after adjuvant treatment could also be at-
tributed to the adjuvant treatment. Therefore, the date of adju-
vant therapy was considered as the last moment of follow-up in
these patients and strictures after that date we not included.
Stricture rates in our cohort were compared with stricture rates
of comparable control groups in the literature. Secondary end-
points included identification of risk factors for stricture devel-
opment, number of endoscopic dilations per patient, type of di-
lation (balloon/bougie), time to dilation after ER (days), num-
ber of patients with dysphagia, number of patients who experi-
enced budesonide side effects, and the number of patients with
adverse events (AEs) after dilation, including the type of AEs. To
investigate whether topical budesonide affects esophageal
stricture treatment, the number of endoscopic dilations per-
formed in patients who developed a stricture in our cohort
was compared with the number of endoscopic dilations per-
formed in patients who developed a stricture in control groups
from the literature.
Statistical analyses
Continuous variables were presented with mean (range) and
median (interquartile range (IQR)) for normally distributed and
skewed data, respectively. Patients who developed a stricture
were compared with patients who did not develop a stricture
after ER to determine potential risk factors for stricture devel-
opment. These two groups were compared with univariable a-
nalysis, performed by the independent Student’s t-test for nor-
mally distributed continuous data and the Chi-square test for
categorical data.
For the comparison of stricture rates and the number of dila-
tions of patients in our cohort with patients who did not receive
a preventive treatment after ER of EC, control groups of several
studies were used in which other methods were investigated to
prevent stricture development. For the selection of these con-
trol groups, a systematic literature search was performed in
Pubmed and Medline by two independent reviewers (S.V. and
M.S). The search strategy and selection of relevant literature is
outlined in Supplementary File 2. Stricture rates in the control
groups were calculated for each study as the total number of
patients who developed a stricture in the control group divided
by the total number of patients in the control group.We calcu-
lated the standard error (SE) for each study using the following
formula: ; where, s = stricture rate and n=
total number of patients in the control group. A fixed-effects
meta-analysis was performed to estimate the stricture rate of
the control studies. To evaluate the heterogeneity between
the studies, the inconsistency index (I2) was calculated [32].
The pooled stricture rate of the control studies was compared
with the stricture rate of our cohort using the Z-test. We used
descriptive statistics to compare the number of dilations of our
study with the number of dilations in control studies; meta-a-
nalysis was not performed since all studies reported different
values of the number of dilations (e. g. median in combination
with range, mean in combination with 95% CI, and no standard
deviations were reported). For all analyses, a two-sided P <0.05
was considered significant. Statistical analyses were performed
with the statistical software IBM SPSS Statistics (version 25) and
Review Manager Software (version 5.3) was used for meta-anal-
ysis.
Results
A total of 64 patients were treated with ER for early EC. After
exclusion of 22 patients (mucosal defect < 50%; n =16, ESD
performed in cardia; n =6), 42 patients received budesonide
therapy after ER. One patient developed ESCC two times, only
the first tumor was included for analysis to prevent bias. Base-
line characteristics of all included patients are presented in
▶Table 1. Most patients were male (n =25; 59.5%) and the
median age was 67.0 years (IQR: 60.8–72.3).
Tumor and treatment characteristics
Tumor and treatment characteristics are presented in ▶Table 2
for 42 cases. Most tumors were located in the mid esophagus
(14/42; 33.3%) and lower esophagus (15/42; 35.7%). The re-
maining tumors (13/42; 31.0%) were overlapping between
two sub-locations or were located in the upper thoracic esoph-
agus. The median circumferential range of the mucosal defect
after ER was 80.0% (IQR: 75.0–100.0). A total of four patients
had a mucosal defect less than 75% and the smallest reported
circumferential range was 60%. The median surface of the re-
sected specimen was 10.3 cm2 (IQR: 6.8–16.7). In total, 25/42
(59.5%) tumors were ESCC and 17/42 (40.5%) tumors were
EAC. There were four patients within the ESCC group with dys-
plasia; three with high-grade dysplasia and one with low-grade
dysplasia. In total, 20 of 42 tumors showed submucosal inva-
sion. In 16 cases, the absolute invasion depth was reported
with a median of 975.0µm (IQR: 562.5–1725.0).
ESD was performed in 37 (88.1%) cases and EMR was
performed in five (11.9%) cases. The dose of oral budesonide
was 2.3mg twice a day (31/42 [73.8%]), 2.3mg budesonide
once a day (6/42 [14.3%]) or 1mg budesonide twice a day (5/42
[11.9%]). One patient discontinued budesonide treatment be-
fore the 6-week period was completed (reason unknown). This
patient used budesonide for 2 weeks and developed a stricture
SE ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðs : ð1 sÞ=nÞ
p
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▶Table 1 Baseline characteristics of 42 patients and univariable analysis of the stricture group (n =18) versus the non-stricture group (n =24).
Characteristics Total (n =42) Stricture (n=18) No stricture (n=24) P value
Sex, n (%) 0.86
▪ Female 17 (40.5%) 7 (41.2%) 10 (58.8%)
▪ Male 25 (59.5%) 11 (44.0%) 14 (56.0%)
Median age, years (IQR) 67.0 (60.8–72.3) 66.0 (60.8–72.5) 67.0 (60.5–72.3) 0.96
ASA classification, n (%) 0.64
▪ I 4 (9.5%) 1 (25.0%) 3 (75.0%)
▪ II 25 (59.5%) 12 (48.0%) 13 (52.0%)
▪ III 13 (31.0%) 5 (38.5%) 8 (61.5%)
Smoking status, n (%) 0.09
▪ Current 12 (31.6%) 3 (25.0%) 9 (75.0%)
▪ Former 18 (47.4%) 8 (44.4%) 10 (55.6%)
▪ Never 8 (21.1%) 6 (75.0%) 2 (25.0%)
▪ Missing 4 1 3
Median pack years (IQR) 42.5 (24.3–48.8) 45.0 (25.5–49.5) 40.0 (19.0–47.5) 0.64
▪ Missing 22 7 15
Alcohol consumption, n (%) 0.25
▪ Current 25 (64.1%) 9 (36.0%) 16 (64.0%)
▪ Former 7 (17.9%) 3 (42.9%) 4 (57.1%)
▪ Never 7 (17.9%) 5 (71.4%) 2 (28.6%)
▪ Missing 3 1 2
Median units alcohol/week (IQR) 10.5 (4.5–21.0) 17.0 (5.8–21.0) 7 (3.3–31.5) 0.57
▪ Missing 12 6 6
IQR, interquartile range; ASA, American Society of Anesthesiologists.
▶Table 2 Univariable analyses of tumor characteristics (42 tumors) and treatment characteristics between the stricture group (n =18) and non-
stricture group (n =24).
Characteristics Total (n=42) Stricture (n=18) No stricture (n=24) P value
Tumor location, n (%)
0.50
▪ Upper thoracic esophagus 4 1 (25.0%) 3 (75.0%)
▪ Mid thoracic esophagus 14 7 (50.0%) 7 (50.0%)
▪ Lower thoracic esophagus 15 5 (33.3%) 10 (66.7%)
▪ Overlapping 9 5 (55.6%) 4 (44.4%)
Median circumferential range of the mucosal defect after ER (%) (IQR) 80 (75–100) 100 (75–100) 75 (75–88) 0.01
Circumferential range of the mucosal defect after ER, n (%) 0.73
▪ 50–74% 3 1 (33.3%) 2 (66.6%)
▪ 75–100% 39 17 (43.6%) 22 (56.4%)
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▶Table 2 (Continuation)
Characteristics Total (n=42) Stricture (n=18) No stricture (n=24) P value
Morphology (Paris classification), n (%) 0.25
▪ Protruded lesions 3 2 (66.7%) 1 (33.3%)
▪ Overlapping protruded/flat elevated lesions 8 4 (50.0%) 4 (50.0%)
▪ Flat elevated lesions 12 2 (22.2%) 10 (83.3%)
▪ Overlapping flat elevated/flat lesions 12 7 (58.3%) 5 (41.7%)
▪ Flat lesions 7 4 (57.1%) 3 (42.9%)
Histology tumor, n (%) 0.41
▪ SCC1 25 12 (48.0%) 13 (52.0%)
▪ Adenocarcinoma 17 6 (35.3%) 11 (64.7%)
Differentiation grade, n (%) 0.32
▪ Well/moderate [G1/G2] 27 13 (48.1%) 14 (51.9%)
▪ Poor [G3] 10 3 (30.0%) 7 (70.0%)
▪ Missing2, 3 5 2 3
Invasion depth, n (%) 0.26
▪ M2 1 0 (0.0%) 1 (100.0%)
▪ M3 16 7 (43.8%) 9 (56.2%)
▪ SM1 1 1 (100.0%) 0 (0.0%)
▪ SM2 8 4 (50.0%) 4 (50.0%)
▪ SM3 9 2 (22.2%) 7 (77.8%)
▪ SMx 2 2 (100.0%) 0 (0.0%)
▪ Missing2, 3 5 2 3
Median surface resection specimen, cm2 (IQR) 10.3 (6.8–16.7) 11.1 (8.7–15.1) 10.3 (5.7–18.1) 0.63
▪ Missing 6 1 5
Median length of the resected specimen, cm (IQR) 4.5 (3.5–5.4) 4.5 (3.8–5.3) 4.4 (3.3–5.7) 0.95
LVI present, n (%) 0.70
▪ Yes 15 6 (40.0%) 9 (60.0%)
▪ Missing3 1 0 1
Vertical resection margin, n (%) 0.78
▪ Positive [R1] 10 4 (40.0%) 6 (60.0%)
▪ Negative [R0] 31 14 (45.2%) 17 (54.8%)
▪ Missing3 1 1
Endoscopic resection method, n (%) 0.27
▪ ESD 37 17 (45.9%) 20 (54.1%)
▪ EMR 5 1 (20.0%) 4 (80.0%)
Dose of budesonide, n (%) 0.93
▪ 2.3mg 2 dd budesonide 31 13 (41.9%) 18 (58.1%)
▪ 2.3mg 1 dd budesonide 6 3 (50.0%) 3 (50.0%)
▪ 1.0mg 2 dd budesonide 5 2 (40.0%) 3 (60.0%)
ER, endoscopic resection; IQR, interquartile range; EC, esophageal carcinoma; SCC, squamous cell carcinoma; LVI, lymphovascular invasion; EMR, endoscopic
mucosal resection; ESD, endoscopic submucosal dissection.
1 Including four patients with high-grade dysplasia (n=3) or low-grade dysplasia (n =1).
2 Not reported for patients with high grade dysplasia (n =3) or low-grade dysplasia (n =1).
3 Resection specimen was lost for pathology review in one patient.
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2 weeks thereafter. Overall, no side effects associated with to-
pical budesonide were reported.
Adjuvant treatment
In total, 16 patients received adjuvant treatment after ER
(▶Fig. 1). The median time between ER and adjuvant treatment
was 81 days (IQR: 48–147). In one patient, adjuvant treatment
started 21 days after ER, before budesonide therapy was com-
pleted. In that patient, the ER specimen showed mucosal ESCC
with LVI. This patient had two synchronous head and neck tu-
mors, therefore, adjuvant radiotherapy was started for both
esophageal and head and neck tumors.
Stricture rate
Eighteen of 42 patients (44.9%) developed a stricture during
follow-up. Patients with a mucosal defect of ≥75% of the
esophageal circumference had a stricture rate of 43.6% (17/
39) (▶Table 2). In this group (n =39) there were 16 cases of
EAC and 23 cases of ESCC. The stricture rate for patients with
EAC in this group was 37.5% (6/16) and for patients with ESCC
47.8% (11/23).
A total of nine studies were selected from the literature
(Supplementary File 2) [19, 21–24,33–36]. Patients in control
groups from these studies all had ESCC and a mucosal defect
after ER with a circumference≥75%. All studies were per-
formed in Asia (5 in Japan, 3 in China, and 1 in Korea). In total,
104 of 147 patients who did not receive preventive treatment
after ER developed a stricture. The stricture rate for these con-
trol groups ranged from 50.0% to 91.7%. Meta-analysis with
fixed-effect model was used to calculate the pooled stricture
rate since I2 was 44% (low heterogeneity). The pooled stricture
rate was 75.3% (95% CI 68.6%-81.9%) (▶Fig. 2). The stricture
rate in our cohort of patients with ESCC and a mucosal defect
after ER with a circumference≥75% was 47.8% and was sig-
nificantly lower compared with the control groups (47.8% vs.
75.3%, P =0.007).
Potential risk factors for stricture development
Patients who developed a stricture were compared with pa-
tients who did not develop a stricture. The stricture group con-
sisted of 18 of 42 patients (44.9%) whereas the non-stricture
group consisted of 24 of 42 patients (57.1%). There was no sig-
Adjuvant therapy
Surgery after 43 & 128 days (n = 2)
CRT after 41 & 77 days (n = 2) 
Active surveillance
Patients preference (n=3)




early esophageal cancer 
(n = 42)*
Mucosal invasion or dysplasia 
(n = 21)
Active surveillance
Patients preference (n = 3)
Poor condition (n = 1)
Adjuvant therapy:
EMR after 176 days (n = 1)
RFA after 444 days (n = 1) 
Adjuvant therapy:
CRT after 21 days (n = 1)
Surgery after 84 days (n = 1) 
Active surveillance 
(patients preference) (n = 2)
Active surveillance (n = 15)
Adjuvant therapy
Surgery after 72–168 days (n = 5)
CRT after 43 & 63 days (n = 2)
RFA after 152 days (n = 1) 
R1 (n = 8)
R0 (n = 12)
R0 (n = 19)
R1 (n = 2)
LVI + (n = 2)
LVI – (n = 17)
▶ Fig. 1 Adjuvant treatment after endoscopic resection of early esophageal cancer.
CRT, chemoradiotherapy; EMR, endoscopic mucosal resection; LVI, lymphovascular invasion; RFA, radiofrequency ablation.
*Resection specimen lost for pathology review in one patient; active surveillance was performed.
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nificant difference in sex, age, smoking status, alcohol con-
sumption, or American Society of Anesthesiologists classifica-
tion between the two groups (▶Table1). The median circum-
ferential range of the mucosal defect in the stricture group
was 100.0% compared with 75.0% in the non-stricture group
(P=0.02) (▶Table 2).
Stricture development and dilations
The median follow-up time for patients who developed a stric-
ture (n=18) was 53.4 weeks (IQR: 17.7–79.5). Dysphagia was
reported in 17 of 18 patients (94.4%). In total, 147 dilations
were performed. The median number of endoscopic dilations
per patient was 6.0 (IQR: 4.0–14.0). The median number of di-
lations in patients with ESCC and a mucosal defect after ER with
a circumference ≥75% was also 6.0 (IQR 2–16). In case of a
stricture, bougie dilation (116/147; 78.9%) was more often
used compared with EBD (31/147; 21.1%). The median time to
dilation after ER was 29.0 (IQR: 20.0–44.5) days. Two patients
developed an AE after dilation. One patient had a poor healing
ulcer after dilation, which was successfully treated with panto-
prazole. Another patient developed a perforation, which was
treated with stent placement. The patient was hospitalized for
2 days for observation without further events. The stent was re-
moved after 4 weeks and the perforation had healed.
The median number of dilations in patients who developed
a stricture in control groups was reported in three studies; 8.1
(range 1–18), 4.5 (range 2–35) and 2 (range 0–15)[21, 22, 34].
Other studies reported the mean number of dilations; 12.5
(95% CI 7.1–17.9) in Takahashi et al., 6.6 (range 0–20) in Ha-
shimoto et al, 3.9 (range 0–17) in Wen et al. (2014) and 13.5
(range 0–28) in Zhou et al [19, 23, 24, 33]. No standard devia-
tions were reported.
Discussion
ER of EC is an excellent minimally invasive treatment method to
cure patients from early EC. A major disadvantage, however, is
development of esophageal strictures after the procedure [10].
Most strictures have been observed when the mucosal defect
after the procedure extends beyond 75% of the esophageal cir-
cumference [10, 13, 14]. We performed a retrospective analysis
of a prospectively collected cohort of patients who received to-
pical budesonide after ER of early EC to investigate whether use
of topical budesonide prevents esophageal strictures after ER.
We found an overall stricture rate of 44.9% in patients who
received 6-week treatment with topical budesonide after ER of
early EC (both ESCC and EAC), compared with a pooled stricture
rate of 75.3% when no preventive measures are taken as re-
ported in the literature [19, 21–24, 33–36]. No side effects of
budesonide were reported. All patients had an esophageal mu-
cosal defect after ER with a circumference≥60%. The median
circumference of the mucosal defect was higher in patients
who developed a stricture compared to patients who did not
develop a stricture (100.0% versus 75.0%; P=0.02). All patients
who developed a stricture were treated with endoscopic dila-
tions, with a median time to dilation of 29.0 days (IQR 20.0–
44.5) and the median number of dilations was 6.0 (IQR 4.0–
14.0). There was only one perforation after dilation, which was
successfully treated with stent placement.
The stricture rate in patients in our study with ESCC and a
mucosal defect≥75% of the esophageal circumference was
47.8%, which is lower than the pooled stricture rate in patients
who did not receive preventive treatment after ER (75.3%; P=
0.007). Topical budesonide therapy seems to be effective for
stricture prevention after ER of early EC. The median number
of dilations performed in patients who developed a stricture in
our cohort (6.0) is in line with the median number of dilations,
Study Stricture rate (%) 95 % CI Weight
Ezoe et al. (21) 91.7 [76.1 – 100.0] 18.1 %
Takahashi et al. (24) 87.5 [71.3 – 100.0] 16.9 %
Zhou et al. (23) 80.0 [55.2 – 100.0] 7.2 %
Hashimoto et al. (19) 75.0 [56.0 – 94.0] 12.3 %
Wen et al. (2014) (33) 72.7 [46.4 – 99.1] 6.4 %
Katoaka et al. (22) 68.8 [46.0 – 91.5] 8.6 %
Hanaoka et al. (34) 65.5 [48.2 – 82.8] 14.8 %
Wen et al. (2016) (35) 63.6 [35.2 – 92.1] 5.5 %
Pih et al. (36) 50.0 [29.1 – 70.9] 10.2 %
Pooled stricture rate 75.3 [68.6 – 81.9] 100.0 %
FE model (Chi2 = 14.40, df = 8, P = 0.07; I2 = 44 %)
0 20 40 60 80 100
▶ Fig. 2 Forest plot of the stricture rate of patients who did not receive a preventive treatment after endoscopic resection of esophageal carci-
noma. CI, confidence interval; df, degree of freedom; FE, fixed-effects; I2, inconsistency index.
van de Ven Steffi Elisabeth Maria et al. Effectiveness of topical… Endoscopy International Open 2020; 08: E1795–E1803 | © 2020. The Author(s). E1801
ranging from 2.0 to 8.1, performed in patients who did not re-
ceive preventive treatment after ER [21, 22, 34]. However, only
three studies reported the median number of dilations without
a standard deviation or IQR. We could therefore not compare
our results with control groups from the literature using meta-
analysis. As a consequence, we could not investigate whether
use of topical budesonide after ER affects esophageal stricture
treatment.
Several studies have investigated different methods of pre-
venting esophageal strictures after ER, such as preventive EBD,
oral prednisolone, triamcinolone injections, and treatment with
viscous budesonide slurry [12, 19, 21–24]. Patients in these
studies had an esophageal mucosal defect with a circumfer-
ence ≥75%, comparable to our study. Although most of these
studies reported a lower stricture rate in the treatment group
compared to the stricture rate in our cohort, several limitations
of these preventive methods are reported and all studies had
small sample sizes with only 13 to 29 patients included in the
treatment group [12, 19, 21–24]. The stricture rate in patients
with ESCC who were treated with preventive EBD after ER was
59% compared to 92% in the control group (P=0.04) [21].
There was no significant difference in the number of dilations
after stricture development in the treatment group compared
to the control group (2.0 vs. 4.5; P=0.05) [21]. Patients in the
treatment group received preventive EBD every week until
complete healing of the mucosal defect was observed, which
could be associated with patient burden and additional costs
[21]. Treatment with oral prednisolone in ESCC patients was re-
ported in two studies and resulted in a significantly lower stric-
ture rate of 17.7% to 23.1% compared with 68.8% to 80.0% in
the control groups [22, 23]. In both studies, the number of re-
quired dilations was significantly higher in the control group
compared to patients receiving oral prednisolone [22, 23]. A
disadvantage of systematic therapy with oral steroids are sever-
al side effects that may occur, such as immune suppression, in-
fections, optical damage, and psychiatric disturbance [25]. Use
of triamcinolone injections after ER in patients with ESCC resul-
ted in a significantly lower stricture rate of 19.0% to 62.5%
compared with 75.0% to 87.5% in control groups [19, 24]. In
both studies, fewer dilations were required in the treatment
groups. A limitation of this invasive method are the extra re-
quired endoscopic procedures, causing additional costs and
potential patient burden. Moreover, there is a risk of developing
perforations after these injections [19]. Bahin et al. reported
the effect of an oral treatment with viscous budesonide slurry
(a mix of budesonide with sucralose) in patients with an EAC
and a significant stricture reduction after EMR was observed
compared to a control group (13.8% vs 37.3%, P < 0.01) [12].
This treatment was only given to patients with an EAC, and pa-
tients with a Barrett segment larger than C3M5 were excluded
[12].
This is the first study to investigate the effect of topical bu-
desonide on stricture prevention after ER of early esophageal
neoplasia. Our study suggests that use of topical budesonide
is safe and effective for prevention of stricture after ER. Topical
budesonide is a noninvasive treatment, which is a major
strength of this study, and no side effects were reported. How-
ever, our results have to be interpreted with caution due to sev-
eral limitations. The first limitation is the retrospective design
of our study, performed in a single center. We had missing
data, which may have influenced our results and could have re-
sulted in information bias. The second limitation is the small
sample size of 42 patients, of whom 18 patients developed a
stricture. Therefore, we could not perform multivariable risk
factor analysis to adjust for confounders. The third limitation is
the non-randomized study design without the availability of a
control group. Because there was no control group, it is impos-
sible to know whether use of topical budesonide was the main
reason for the lower stricture rate. Another limitation is the po-
tential for selection bias. The endoscopist decided whether pa-
tients received budesonide after ER, based on the estimated
risk of developing strictures. Further, although patients all re-
ported taking the medication correctly during follow-up, we
did not have a formal procedure in place to confirm that. Be-
cause no topical budesonide tablets were available during the
largest part of the study period, we prescribed the dispersible
budesonide tablets from a budesonide enema. This off-label
use could result in incorrect use of budesonide. Moreover, dif-
ferent doses of budesonide were used during the study period.
It seems likely that an orodispersible tablet designed for this in-
dication could yield an even higher effect in prevention of stric-
tures. To address these limitations, a prospective, randomized
controlled trial (RCT) is necessary to investigate the efficacy
and tolerability of budesonide orodispersible tablets.
Conclusion
In conclusion, based on comparisons with historical published
data, topical budesonide after ER for EC seems to be an effec-
tive method for preventing stricture development. The stric-
ture rate was lower compared with the rates in patients who
did not receive a preventive method after ER. However, a pro-
spective RCT is required to investigate whether topical budeso-
nide is safe and effective for prevention of strictures after ER in
patients with early stage EC, and whether topical budesonide
affects esophageal stricture treatment.
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